David Chapman obtained his PhD from the University of Utah. He has several years of experience testing antiseizure medications in preclinical models of epilepsy, and more than two decades of industry experience in Medical Affairs, predominantly in Epilepsy and Neurological Rare Diseases. Prior to joining Lundbeck in 2024, Dave was most recently at Longboard Pharmaceuticals. He is committed to providing solutions to patients and families living with rare neurological conditions. Dave recently relocated to Utah with his wife, Kim. Their four adult children (and 3 grandchildren) have fled the state.